Proinflammatory state promotes red blood cell alloimmunization in pediatric patients with sickle cell disease

Yan Zheng,[1] Jeffrey M. Gossett,[2] Pei-Lin Chen,[3] Martha Barton,[3] Missy Ryan,[1] Jing Yu,[1] Guolian Kang,[2] Jane S. Hankins,[3] and Stella T. Chou[4]

[1]Department of Pathology, [2]Department of Biostatistics, and [3]Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN; and [4]Departments of Pediatrics and Pathology, The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA

Key Points

- Transfusion during proinflammatory events increases alloimmunization in patients with sickle cell disease, which is not mitigated by HU.

- High transfusion burden and HbSS and HbSβ⁰–thalassemia genotypes are additional risk factors for alloimmunization.

We examined risk factors for red blood cell (RBC) alloimmunization in pediatric patients with sickle cell disease, focusing on the recipients' inflammatory state at the time of transfusion and anti-inflammatory role of hydroxyurea (HU). Among 471 participants, 55 (11.70%) participants were alloimmunized and formed 59 alloantibodies and 17 autoantibodies with an alloimmunization rate of 0.36 alloantibodies per 100 units. Analysis of 27 participants in whom alloantibodies were formed with specificities showed 23.8% (30/126) of units transfused during a proinflammatory event resulting in alloantibody formation compared with 2.8% (27/952) of units transfused at steady state. Therefore, transfusion during proinflammatory events increased the risk for alloimmunization (odds ratio [OR], 4.22; 95% confidence interval [CI], 1.64-10.85; P = .003). Further analysis of all the 471 participants showed that alloimmunization of patients who received episodic transfusion, mostly during proinflammatory events, was not reduced with HU therapy (OR, 6.52; 95% CI, 0.85-49.77; P = .071), HU therapy duration (OR, 1.13; 95% CI, 0.997-1.28; P = .056), or HU dose (OR, 1.06; 95% CI, 0.96-1.16; P = .242). The analysis also identified high transfusion burden (OR, 1.02; 95% CI, 1.003-1.04; P = .020) and hemoglobin S (HbSS) and HbSβ⁰–thalassemia genotypes (OR, 11.22, 95% CI, 1.51-83.38; P = .018) as additional risk factors for alloimmunization. In conclusion, the inflammatory state of transfusion recipients affects the risk of RBC alloimmunization, which is not modified by HU therapy. Judicious use of transfusion during proinflammatory events is critical for preventing alloimmunization.

Introduction

Sickle cell disease (SCD) is one of the most common inherited diseases, affecting ~100 000 people in the United States.[1] Red blood cell (RBC) transfusion is essential for preventing and managing the acute and chronic complications of SCD. More than 50% of pediatric and 90% of adult patients with SCD receive at least one RBC transfusion in their lifetime.[2] A remaining challenge of blood transfusion is RBC alloimmunization. The alloimmunization rate is as high as 1.94 alloantibodies per 100 units with ABO- and RhD-antigen matching and down to 0.40 alloantibodies per 100 units with additional Rh (C, E or C, c, E, e) and K antigen matching.[3] RBC alloimmunization increases the risk of acute and delayed

---

The full-text version of this article contains a data supplement.

hemolytic transfusion reactions and hyperhemolysis syndrome, leading to severe anemia and even death.[4-8] RBC alloimmunization may also result in transfusion delays, secondary to challenges in identifying compatible RBC units that lack the target antigens. Overall, alloimmunization reduces the survival rate of patients with SCD.[9,10]

Alloantibody formation can be attributed to multiple potential risk factors including older age, female sex, high transfusion load, presence of autoantibodies, and aging RBCs.[11-14] For patients with SCD, the disparate expression of RBC antigens between blood recipients of African-descent and White donors[2,15] and the high frequency of variant Rh antigens in both patients and donors of African descent[16-18] contribute to the higher rate of alloimmunization compared with other populations that underwent transfusion. Transfusion during proinflammatory events also increases the risk of alloimmunization in patients with SCD.[19] Hydroxyurea (HU), which is increasingly used for SCD preventive therapy, induces myelosuppression and reduces inflammation,[20,21] but its effect on alloimmunization has not been investigated. Here, we conducted a single-center retrospective cohort study in pediatric patients with SCD to explore the risk factors for alloimmunization, focusing on the roles of the recipients' proinflammatory state, HU therapy, and Rh variants in alloimmunization.

Methods

Study subjects

We conducted a single-center retrospective cohort study on RBC alloimmunization in pediatric patients with SCD who participated in the Sickle Cell Clinical Research and Intervention Program. The Sickle Cell Clinical Research and Intervention Program study is a lifetime cohort study that collects retrospective and prospective data on clinical, neurocognitive, geographical, psychosocial, and health outcomes in children, adolescents, and adults with SCD.[22] This study was approved by the St. Jude Institutional Review Board and performed in accordance with the Declaration of Helsinki. Patient inclusion criteria were as follows: (1) age <19 years at the time of transfusion, (2) diagnosis of SCD of any genotype, and (3) recipient of at least 1 RBC transfusion at our center before 31 December 2017 or 1 day before the 19th birthday (whichever came first).

RBC transfusion and alloimmunization

Relevant clinical data before 31 December 2017 or 1 day before the 19th birthday of the included patients (whichever came first) were collected. The cutoff date for antibody screens was extended to 19 September 2022 because many patients who received episodic transfusion did not have follow-up screens until a later date after the end of the study. RBC units transfused to patients with SCD were prestorage leukoreduced, irradiated, and hemoglobin (Hb) S–negative. Prophylactic Rh (C and E)– and K–negative or matched RBCs were provided to patients with SCD at our center since 2002. RBCs administered also lacked any antigens against which antibodies were previously identified. Chronic transfusion was defined as requiring regularly scheduled transfusions for any indication. Transfusions before alloimmunization was defined as RBC units received at least 7 days before the first newly identified antibody. RBC antibody screens and identification were performed using tube-testing method. Here, autoantibodies

with Rh specificity were classified as alloantibodies because these were likely alloantibodies associated with variant Rh antigens. The alloimmunization incidence rate was calculated as the number of alloantibodies divided by the total number of RBC units transfused by 31 December 2017 or 1 day before the 19th birthday (whichever came first).

Assessing the association of receiving transfusion during proinflammatory events with alloimmunization

For this analysis, only patients who were alloimmunized were considered. In addition, patients who were previously alloimmunized but did not form new antibodies after transferring to our center and those with only autoantibodies, antibodies of undetermined specificity, or antibodies against low-frequency antigens were excluded (supplemental Figure 1). RBC units received at least 7 days before the last newly identified alloantibody in the patients were included. Next, the units were categorized based on their proximity to the date of a newly identified alloantibody and a proinflammatory event. Proinflammatory events were defined as emergency department visits and hospitalization for acute chest syndrome (ACS), acute stroke, acute febrile illness in the absence of other SCD complications, vaso-occlusive crisis, splenic sequestration, priapism, parvovirus B19–induced transient aplastic crisis, and elective surgery, as previously described.[19] Among the included RBC units, the units received during a transfusion event closest to a newly identified alloantibody were categorized as antibody-positive transfusions, and the remaining ones were categorized as antibody-negative transfusions; the units received during a transfusion event ≤8 days before or after a proinflammatory event were categorized as transfusions during proinflammatory events, and the remaining ones were categorized as transfusions at steady state. If >1 unit of RBCs were transfused during a transfusion event or clinical encounter, all units were grouped in the same category. Laboratory results of the Hb level at least 7 days before a transfused unit, and those of the absolute reticulocyte count, maximum white blood cell count, absolute neutrophil count, lactate dehydrogenase, and total bilirubin at least 7 days before and after a transfused unit were also included in the analysis. Notably, for analysis by transfusion events, the same laboratory results were used for all the transfused units in a transfusion event.

Statistical analysis

Patient characteristics were summarized based on the alloimmunization status. Continuous variables were summarized as the median and interquartile range (IQR), and categorical variables were summarized in terms of number and percentage. To investigate the association of alloimmunization and receiving transfusions during proinflammatory events, we first used generalized linear mixed models with a binomial error distribution to assess the association of alloimmunization with age at the time of transfusions for the patients who met the inclusion criteria. The remaining clinical variables were then analyzed with an adjustment for age at the time of transfusions. The models included a random intercept for subjects to account for the clustering of values from the same subject. The models were fit using the Glimmix procedure in Statistical Analysis System (SAS). To examine the roles of antiinflammatory agent, HU and other clinical variants in alloimmunization, logistic regression models were used to assess the association of each potential risk factor with alloimmunization with an

adjustment for the time of patients on the study, which we calculated as the time from which the patient received first RBC transfusion at our center to the first new antibody identified for patients who were alloimmunized or to 31 December 2017 or 1 day before the 19th birthday (whichever came first) for patients who were not alloimmunized. Risk factors with $P < .1$ and the time on the study were entered as candidate predictors into a multivariate logistic regression model based on a backward selection procedure. The time on the study was not forced into the final model. Transfusion load (RBC units) or transfusion frequency (chronic vs episodic transfusions) was included as a candidate predictor in the multivariate logistic regression model because of a strong correlation between the 2 variables using a multicollinearity test with a variance inflation factor <2. P values were considered significant if $P < .05$. All reported P values were 2-sided. Statistical analyses were performed with SAS software, version 9.4, for Windows (SAS Institute Inc, Cary, NC).

Results

Clinical characteristics of the study subjects

A total of 471 patients were included in the study (Table 1). The mean patient age at the end of the study was 12.9 ± 5.2 years. Female patients accounted for 48.6% (n = 229) of the study population. Almost all patients self-identified as Black (n = 467; 99.2%). HbSS and HbSβ⁰–thalassemia were the most common Hb genotypes (n = 384; 81.5%). The 471 patients received a total of 15 960 units of RBCs. The median age at first transfusion was 4.6 years (interquartile range [IQR], 1.9-8.1 years) and the median total transfusion period was 6.4 years (IQR, 3.5-10.3 years). The median total RBC exposure was 3 units per patient (IQR, 2-9 units/patient). Most patients (n = 391, 85.0%) received episodic transfusion and had a median total of 3 units per patient (IQR, 1-5 units/patient). Sixty-nine (15.0%) patients required chronic transfusion and received a median total of 143 units per patient (IQR, 70-312 units/patient). Most patients who received episodic transfusion (n = 298, 76.2%) were also treated with HU. HU was initiated at a median age of 5.7 years (IQR, 2.9-9.4 years), the median accumulative therapy duration was 4.37 years (IQR, 2.49-8.31 years), and the median maximum tolerated dose (MTD) was 29.2 mg/kg per day (IQR, 23.6-30.8 mg/kg per day). Patients who received chronic transfusion might receive HU before starting chronic transfusion, but it was very rare to have concurrent chronic transfusion and HU therapy.

RBC alloimmunization

Among the 471 participants, 55 were alloimmunized, including 11 patients who had been alloimmunized before receiving transfusions at our center (Table 1). A total of 76 antibodies were identified among the whole cohort, including 59 alloantibodies and 17 autoantibodies (and including 10 alloantibodies and 3 autoantibodies from the 11 patients who were previously alloimmunized; Figure 1). The time to antibody detection from the last transfusion was 110 days (IQR, 23-439 days) for patients who received episodic transfusion and 28 days (IQR, 26-32 days) for patients who received chronic transfusion. The most common antibody specificity was anti-D and anti-M (n = 6 for both, 7.9%). Notably, all the anti-Ms were identified at least 7 days after transfusions. Fifteen antibodies were against Rh antigens despite transfusion with

prophylactic Rh (D, C, and E)-negative or -matched RBCs. The alloimmunization prevalence in our patient cohort was 11.7% (55/471), and the alloimmunization incidence rate was 0.36 alloantibodies per 100 transfusions (59 alloantibodies per 15 960 RBC units). Antibodies were first detected at a median age of 9.9 years (IQR, 6.0-14.0 years) after a median of 17 units of RBCs (IQR, 3-61 units; Table 1). In total, 36.2% (25/69) of chronically transfused patients were alloimmunized and had formed their first antibody after receiving a median of 55 units (IQR, 31-90 units); 4.9% (19/391) of episodically transfused patients were alloimmunized after a median of 2 units (IQR, 2-5 units). For the patients who were alloimmunized while receiving episodic transfusion, 94.7% (18/19) of the patients were managed with HU. HU was started at a median age of 3.5 years (IQR, 2.1-7.2 years); the median therapy duration was 4.50 years (IQR, 0.67-6.79 years), and the median MTD was 30.0 mg/kg per day (IQR, 28.3-30.1 mg/kg per day) before alloimmunization. Notably, the changes in HbF percentage and mean corpuscular volume from baseline to 1 and 2 years after starting HU were similar among the alloimmunized and non-alloimmunized patients, suggesting similar HU adherence across both groups (supplemental Table 1).

Assessing the effect of proinflammatory events on alloimmunization

Because exposure to a foreign RBC antigen does not always lead to alloantibody formation, other factors such as recipients' inflammatory state at the time of transfusion can contribute as well. To investigate whether RBC transfusion during proinflammatory events results in a higher risk of alloantibody formation than that at steady state, we analyzed the transfusions received by the patients who were alloimmunized with determined alloantibody specificities. Of the 55 patients who were alloimmunized, 27 patients were analyzed after excluding 11 patients who were previously alloimmunized but did not form new antibodies at our center and 17 patients with only autoantibodies, antibodies of undetermined specificity, or antibodies against low-frequency antigens (supplemental Figure 1). Patients with antibodies against low-frequency antigens only were excluded on the basis that the chances to encounter low-frequency antigens during proinflammatory events and at steady state are very low. The 27 patients received 1078 RBC units before 35 new alloantibodies were identified with a median time until antibody detection of 36 days (IQR, 28-184 days; Table 2; supplemental Table 2). Among the 1078 transfused units, 126 units were administered during a proinflammatory event, and 952 units administered at steady state; 57 units were associated with subsequent alloantibody positivity, and 1021 units were not. Specifically, 30 of the 126 (23.8%) units transfused during a proinflammatory event resulted in alloantibody production, compared with 27 of 952 (2.8%) units received at steady state. Therefore, alloantibodies were 4.22-fold likely to form after transfusions received during a proinflammatory event (95% confidence interval [CI], 1.64-10.85; $P = .003$). Among the proinflammatory events, parvovirus B19–induced transient aplastic crisis was associated with an increased risk of alloimmunization (odds ratio [OR], 187.76; 95% CI, 4.67-7542; $P = .006$), but no association was found for other SCD complications such as ACS (OR, 1.24; 95% CI, 0.05-29.12; $P = .894$) as reported previously.[19] We did not observe a correlation between alloimmunization and the Hb level (OR, 0.79; 95% CI, 0.54-1.14; $P = .203$),

Table 1. Patient demographics and clinical characteristics

Clinical variables	Total n = 471 (%)	Alloimmunized, n = 55 (%)*	Nonalloimmunized, n = 416 (%)
Sex			
Female	229 (48.6%)	28 (50.9%)	201 (48.3%)
Male	242 (51.4%)	27 (49.1%)	215 (51.7%)
Race			
Black	467 (99.2%)	55 (100.0%)	412 (99.0%)
Black and White	1 (0.2%)	–	1 (0.2%)
White	2 (0.4%)	–	2 (0.5%)
Others	1 (0.2%)	–	1 (0.2%)
Hb genotypes			
SS/Sβ^0 thalassemia	384 (81.5%)	50 (90.9%)	334 (80.3%)
SC	65 (13.8%)	3 (5.5%)	62 (14.9%)
Sβ^+ thalassemia	20 (4.2%)	2 (3.6%)	18 (4.3%)
Others	2 (0.4%)	–	2 (0.5%)
Blood transfusion			
Age at first transfusion (y)	4.6 (~1.9-8.1)	4.9 (~2.7-6.8)	4.5 (1.7-~8.3)
Transfusion period (y)			
Total	6.4 (~3.5-10.3)	6.9 (~4.0-11.9)	6.3 (~3.3-10.2)
Before alloimmunization	–	4.1 (~0.9-7.8)	–
Transfusion load (units)			
Total	3 (~2-9)	16 (~3-168)	3 (~1-7)
Before alloimmunization	–	17 (~3-61)	–
Transfusion frequency			
Chronic transfusion			
No. of patients	69 (15.0%)	25 (56.8%)	44 (10.6%)
Transfusion load (units)			
Total	143 (~70-312)	168 (~84-293)	138 (~62-315)
Before alloimmunization	–	55 (~31-90)	–
Episodic transfusion			
No. of patients	391 (85.0%)	19 (43.2%)	372 (89.4%)
Transfusion load (units)			
Total	3 (~1-5)	5 (~2-9)	3 (~1-5)
Before alloimmunization	–	2 (~2-5)	–
HU treatment			
Yes	298 (76.2%)	18 (94.7%)	280 (75.3%)
No	93 (23.8%)	1 (5.3%)	92 (24.7%)
Age starting HU (y)	5.7 (~2.9-9.4)	3.5 (~2.1-7.2)	5.8 (~2.9-9.4)
HU therapy duration (y)†			
Total	4.37 (~2.49-8.31)	7.73 (~4.84-9.56)	4.20 (~2.40-8.26)
Before alloimmunization	–	4.50 (~0.67-6.79)	–
HU MTD (mg/kg per d)			
Total	29.2 (~23.6-30.8)	30.0 (~28.3-30.1)	29.0 (~23.0-31.0)
Before alloimmunization	–	30.0 (~28.3-30.1)	–

Categorical variables summarized as n (%), and continuous variables summarized as median (IQR, Quartile 1 to Quartile 3).

*Among 55 patients who were alloimmunized, 11 were alloimmunized before transfusion at our center. Their data about sex, race, and Hb genotypes were included for alloimmunization association analysis. Their histories of blood transfusion and HU therapy before alloimmunization were unknown so were not included in the analysis.

†Included episodically transfused patients who received HU therapy only.

Figure 1. Antibodies identified in pediatric patients with SCD. *Indicates antibodies found in D- or e-positive patients showing D or e specificities, respectively. **Indicates antibodies against low-frequency antigens without determined specificity.

absolute reticulocyte counts (OR, 185.88; 95% CI, 0.05-698390; $P = .212$), white blood cell counts (OR, 0.99; 95% CI, 0.91-1.08; $P = .859$), absolute neutrophil count (OR, 0.95; 95% CI, 0.84-1.09; $P = .487$), lactate dehydrogenase (OR, 0.99; 95% CI, 0.67-1.45; $P = .943$), or total bilirubin (OR, 1.15; 95% CI, 0.85-1.55; $P = .368$) around the time of transfusions. We also analyzed the

data based on transfusion events (Table 3). Among the 583 transfusion events, 20 of 97 (20.6%) transfusion events during a proinflammatory event led to alloantibodies formation compared with 13 of 486 (2.7%) transfusion events at steady state. Thus, transfusions during proinflammatory events increased the risk of alloantibody formation up to 7.85-fold (95% CI, 2.98-20.65;

Table 2. Transfusion under proinflammatory conditions increases the risk of alloimmunization (based on RBC units)

Clinical variables	Alloantibody-positive transfusions, n = 57 units	Alloantibody-negative transfusions, n = 1021 units	OR (95% CI)*	P value
Proinflammatory events				
Yes	30 (52.6%)	96 (9.4%)	4.22 (1.64, 10.85)	**.003**
No	27 (47.4%)	925 (90.6%)	–	–
Aplastic crisis				
Yes	4 (7.0%)	1 (0.1%)	187.76 (4.67, 7542)	**.006**
No	53 (93.0%)	1020 (99.9%)	–	–
Laboratory tests				
Hb (g/dL)	9.90 (8.10~10.40)	10.60 (9.50~11.30)	0.79 (0.54, 1.14)	.203
Absolute reticulocyte count (10^6/μL)†	0.26 (0.15~0.34)	0.19 (0.15~0.25)	185.88 (0.05, 698390)	.212
WBC (10^3/μL)‡	11.10 (6.30~15.15)	8.30 (6.30~11.90)	0.99 (0.91, 1.08)	.859
ANC ((/μL)§	6350 (3350~8100)	3600 (2300~6800)	0.95 (0.84, 1.09)	.487
LDH (unit/L)	472 (384~517)	415 (356~520)	0.99 (0.67, 1.45)	.943
Total bilirubin (mg/dL)	4.20 (2.50~6.40)	2.30 (1.50~3.80)	1.15 (0.85, 1.55)	.368

Categorical variables summarized as n (%). Continuous variables summarized as median (IQR, from Quartile 1 to Quartile 3). Indicated in bold, $P < 0.05$ is considered significant. ANC, absolute neutrophil count; LDH, lactate dehydrogenase; WBC, white blood cell.

*The analyses included transfusions (units) up to 7 days before all newly identified alloantibodies. Since antibody-positive transfusions usually occurred at a later time than antibody-negative transfusions for an individual patient (OR by RBC units: 1.31, 95% CI: 1.11–1.56, $P = 0.002$), the association analyses were adjusted for patient age at the time of transfusions.

†Exclude absolute reticulocyte counts during aplastic crisis.

‡The maximum WBC counts during 7 days before and after the indicated transfused unit/transfusion event.

§OR for ANC was based on a 1000-unit increase. The ORs for the remaining laboratory results were based on a 1-unit increase.

Table 3. Transfusion under proinflammatory conditions increases the risk of alloimmunization (based on transfusion events)

Clinical variables	Alloantibody-positive transfusions, n = 33 events	Alloantibody-negative transfusions, n = 550 events	OR (95% CI)*	P value
Proinflammatory events				
Yes	20 (60.6%)	77 (14.0%)	7.85 (2.98, 20.65)	**<.001**
No	13 (39.4%)	473 (86.0%)	–	–
Aplastic crisis				
Yes	3 (9.1%)	1 (0.2%)	87.86 (2.83, 2727)	**.011**
No	30 (90.9%)	549 (99.8%)	–	–
Laboratory tests				
Hb (g/dL)	9.10 (~7.80-10.40)	9.80 (~9.10-10.80)	0.63 (0.43, 0.94)	**.023**
Absolute reticulocyte count (10^6/μL)†	0.26 (~0.15-0.34)	0.21 (~0.17-0.28)	146.43 (0.01, 2644816)	.317
WBC (10^3/μL)‡	12.40 (~9.90-16.45)	10.60 (~6.90-14.20)	1.03 (0.94, 1.12)	.517
ANC ((/μL)§	7400 (~5800-8500)	5748 (~2800-8200)	1.01 (0.88, 1.16)	.869
LDH (unit/L)	495 (~409-653)	460 (~367-544)	1.29 (0.94, 1.79)	.118
Total bilirubin (mg/dL)	3.50 (~1.50-5.50)	2.80 (~1.60-3.80)	1.01 (0.73, 1.40)	.951

Categorical variables summarized as n (%). Continuous variables summarized as median (IQR, from Quartile 1 to Quartile 3). Indicated in bold, P < 0.05 is considered significant.

*The analyses included transfusions (events) up to 7 days before all newly identified alloantibodies. Because antibody-positive transfusions usually occurred at a later time than antibody-negative transfusions for an individual patient (OR based transfusion events, 1.20; 95% CI, 1.02-1.41; P = .028), the association analyses were adjusted for patient age at the time of transfusions.

†Exclude absolute reticulocyte counts during aplastic crisis.

‡The maximum WBC counts 7 days before and after the indicated transfused unit per transfusion event.

§OR for ANC was based on a 1000-unit increase. The ORs for the remaining laboratory results were based on a 1-unit increase.

P < .001). Parvovirus B19–induced transient aplastic crisis was associated with an increased risk of alloimmunization (OR, 87.86; 95% CI, 2.83-2727; P = .011), but not other complications, including ACS (OR, 1.29; 95% CI, 0.08-20.61; P = .856). We also found that the Hb level was negatively correlated to alloimmunization (OR, 0.63; 95% CI, 0.43-0.94; P = .023). The median RBC units per transfusion event were 1.00 (IQR, 1.00-2.00) for the alloantibody-positive transfusion events, 1.00 (IQR, 1.00-2.00) for the alloantibody-negative ones, and not significantly different (OR, 0.99; 95% CI, 0.60-1.62; P=.967). Thus, alloantibody formation was not due to the increased number of units transfused during the alloantibody-positive transfusion events.

Determining the effects of HU therapy and other risk factors on alloimmunization

Because recipient inflammatory state at the time of transfusion influenced the risk of alloimmunization, we examined the roles of anti-inflammatory agent HU and other clinical variables in alloimmunization (Table 4). For this analysis, the entire study cohort of 471 patients was included. For the 11 patients who had been previously alloimmunized before transfusion at our center, only their sex, race, and Hb genotype were included in the analysis. Logistic regression analysis demonstrated that for episodically transfused patients who received transfusion mostly during proinflammatory events, neither did the HU receipt affect their likelihood of alloimmunization (OR, 6.52; 95% CI, 0.85-49.77; P = .071), nor the HU duration (OR, 1.13; 95% CI, 0.997-1.28; P = .056), nor the HU MTD (OR, 1.06; 95% CI, 0.96-1.16; P = .242). Instead, the analysis identified HbSS and HbSβ⁰–thalassemia genotypes (OR, 12.14; 95% CI, 1.64-89.86; P = .015), high transfusion load (OR, 1.02; 95% CI, 1.01-1.04; P = .007), and frequent RBC exposure or chronic transfusion (OR, 17.64; 95% CI, 8.19-38.00; P < .001)

as the risk factors for alloimmunization. Because chronic transfusion usually results in high transfusion load, we performed multivariate logistic analyses with transfusion load and transfusion frequency, respectively. The multivariate logistic analysis including transfusion load showed that the HbSS and HbSβ⁰–thalassemia genotypes (OR, 11.22; 95% CI, 1.51-83.38; P = .018) and high transfusion load (OR, 1.02; 95% CI, 1.003-1.04; P = .020) were significantly associated with alloimmunization. The multivariate logistic analysis including transfusion frequency identified chronic transfusion (OR, 14.19; 95% CI, 6.54-30.80; P < .0001) as a significant risk factor for alloimmunization. Hb genotypes were no longer significantly associated with alloimmunization (OR, 5.84; 95% CI, 0.76-45.67; P= .089).

Effect of *RH* genotypes on Rh alloimmunization

Variant *RH* alleles are common in patients with SCD. Approximately 30% of our patients have whole-genome sequencing (WGS) data, which allowed us to obtain their *RH* genotypes using RHtyper, an automated algorithm for accurate and high throughput *RH* genotyping using WGS data.[23] Eleven patients formed a total of 14 anti-Rh, of which 9 patients (with 10 anti-Rh) had WGS data from which *RH* genotypes were obtained (Table 5). One patient (#7) with *RHCE*Ce/RHCE*ce48C* formed an anti-c, although *RHCE*ce48C* is a common *RHCE* allele in individuals of African ancestry and not associated with partial ce expression.[17,23] Five patients (#1-4 with D specificity and #9 with e specificity) are heterozygous for the corresponding conventional *RH* alleles, and, thus, these antibodies could be autoantibodies or alloantibodies driven by Black blood donors with immunogenic Rh variants that were recognized as foreign by the patients.[17] Four patients (#4, 5, 6, and 8) had anti-C or anti-E despite receiving C– or E–negative units, which might have been stimulated by donors with Rh variants

Table 4. Risk factors associated with alloimmunization in patients with SCD

Clinical variables	Logistic regression analysis*		Multivariate logistic regression analysis using transfusion load		Multivariate logistic regression analysis using transfusion frequency	
	Adjusted OR (95% CI)	P value	Adjusted OR (95% CI)	P value	Adjusted OR (95% CI)	P value
All patients						
Age at first transfusion (y)	0.96 (0.90, 1.03)	.31	–	–	–	–
Sex, male vs female	0.90 (0.48, 1.69)	.75	–	–	–	–
Hb genotype, SS/Sβ⁰ thalassemia vs Others†	12.14 (1.64, 89.86)	.015	11.22 (1.51, 83.38)	**.018**	5.84 (0.76, 45.67)	.089
Transfusion load (units)‡	1.02 (1.01, 1.04)	.007	1.02 (1.003, 1.04)	**.020**	–	–
Transfusion frequency, Chronic vs Episodic	17.64 (8.19, 38.00)	< .001	–	–	14.19 (6.54, 30.80)	**< .0001**
Patients who received episodic transfusion						
HU yes/no	6.52 (0.85, 49.77)	.071	–	–	–	–
HU therapy duration	1.13 (0.997, 1.28)	.056	–	–	–	–
HU MTD (mg/kg per d)	1.06 (0.96, 1.16)	.242	–	–	–	–

Indicated in bold, $P < 0.05$ is considered significant.

*Adjusted for time on study, which is from patients receiving the first RBC transfusion at our center to the first newly identified antibody for patients who were alloimmunized, and to 31 December 2017 or one day before patients turning 19 years old (whichever came first) for patients who were not alloimmunized.

†Others include all non-HbSS/Sβ⁰–thalassemia genotypes.

‡OR was based on a 5-unit increase.

as well. Given the small number of patients with anti-Rh in our cohort, we were unable to test the association of *RH* genotypes with Rh alloimmunization statistically.

Discussion

In this retrospective cohort study, we examined RBC alloimmunization and its associated risk factors in pediatric patients with SCD who received Rh— and K—negative or matched RBCs. The

Table 5. *RH* genotypes of patients with Rh antibody specificities

Patient	Rh antibody specificity	RH genotype	
		RHD*	RHCE*
1	D	RHD	ce48C
		DAU3	Ce
2	D	RHD	ce733G
		DAU0	ce48C
3	D	RHD	ce
		Pseudogene/ Ψ	ce48C
4	D and C (big)	RHD	ce48C,105T
		DAU0	ce733G
5	C (big)	Deletion	ce733G
		Deletion	ce
6	C (big)	Deletion	ce48C
		DAU0	ce
7	c (little)	RHD	Ce
		RHD	ce48C
8	E	Deletion	ceTI
		DIVa	ceAG
9	e (little)	RHD	cE
		RHD	ce

alloimmunization prevalence was 11.7% and the alloimmunization rate was 0.36 alloantibodies per 100 transfusions. We found that receiving transfusions during proinflammatory events increased the risk of alloimmunization. HU did not reduce the likelihood of alloimmunization for episodically transfused patients who typically require transfusion during proinflammatory events. The risk of alloimmunization was also higher for patients with HbSS and HbSβ⁰–thalassemia genotypes and those with a high transfusion burden. High transfusion burden is associated with a higher likelihood of encountering a foreign donor RBC antigen. Therefore, alloimmunization is determined by foreign RBC antigen exposure as well as the context under which a foreign RBC antigen is exposed.

Receiving transfusions during an inflammatory state promotes alloimmunization in murine models.[24] In human studies, increased alloimmunization occurs in inflammation-associated conditions, including autoimmune diseases, febrile nonhemolytic transfusion reactions, and infections.[25-28] Fasano et al examined 52 alloimmunized patients with SCD and found that transfusions during proinflammatory events increased the risk of alloantibody formation by 8.9-fold.[19] We analyzed 27 alloimmunized patients with SCD and found that transfusion during proinflammatory events was associated with a 4.22-fold higher risk for alloimmunization, albeit slightly lower than the previously reported. Notably, Fasano et al used varied levels of RBC antigen matching in their study, and up to 28% of transfused RBC units were matched for ABO and RhD antigens only. The majority of our patients received Rh (C and E)— and K—negative or matched units, which likely decreased the overall risk of alloimmunization, even during proinflammatory events. Fasano et al also found that among complications of SCD, ACS (OR, 16.7; 95% CI, 10.7-26.4; $P < .001$) was strongly associated with alloimmunization. We did not find ACS affecting the risk of alloimmunization. Instead, we identified that transient aplastic crisis promoted alloimmunization. However, because of the low case number of aplastic crisis in our study, further studies are warranted.

SCD is an inflammatory disease, partly because of chronic hemolysis.[29] Upon hemolysis, Hb is released from RBCs and oxidized into heme, which induces sterile inflammation via the toll-like receptor−4 and inflammasome signaling. The inflammatory milieu in SCD is characterized by activated neutrophils, monocytes, and lymphocytes as well as increased cytokines and chemokines in the plasma. The inflammation is further escalated during acute complications of SCD, such as ACS and vaso-occlusive crisis because of increased hemolysis and potentially concomitant infections.[30-32] In addition, patients who receive alloimmunization demonstrate abnormalities in monocyte or macrophage function, T-cell differentiation, and B-cell maturation and activation.[24,33,34] Therefore, the augmented inflammatory milieu present during SCD acute complications may exacerbate the already abnormal immune response of those patients, facilitating RBC alloantigen recognition and subsequent alloantibody formation.

Most patients with SCD are treated with HU at our center. HU, a ribonucleotide reductase inhibitor, blocks cellular proliferation by arresting cell cycle at the G1-S interface leading to myelosuppression. Patients receiving HU have lower numbers of neutrophils, monocytes, lymphocytes, and natural killer cells.[35] HU also reduces neutrophil adhesion and monocyte inflammatory potential, resulting in decreased plasma levels of various cytokines and chemokines.[21,36-38] Despite these anti-inflammatory effects, our study found that HU therapy did not decrease alloimmunization in patients who received episodic transfusion, and the reasons can be multifactorial. HU improves but does not correct the SCD-associated inflammation. Patients with SCD treated with HU still have higher levels of cytokines and chemokines than age and race−matched healthy controls.[21,36] Episodically transfused patients usually receive transfusions to manage acute SCD complications, and HU has been reported insufficient to dampen the further augmented inflammation associated with the acute complications.[31] Furthermore, HU inhibits T-cell proliferation but does not affect T-cell activation, as evidenced by effective immunization to various vaccines despite HU use.[39,40] Although HU may not reduce the risk of alloimmunization directly, HU may decrease alloimmunization indirectly by lowering the overall donor exposure because it minimizes acute SCD-related events requiring transfusion.[41-43] Given the benefits of HU in preventing and treating acute SCD complications,[41-44] HU treatment should be continued during episodes of complications.

Our finding that high transfusion load is associated with alloimmunization is consistent with previous studies.[12,45-47] Distinct from prior studies, we found high transfusion load was a significant risk factor yet with a relatively low OR (OR: 1.02; 95% CI: 1.003-1.04; $P < .020$). This is likely explained by our use of transfused units up to the first alloimmunization event, whereas prior studies used total transfused units regardless of the timing of antibody formation. The rationale for defining transfusion load as units transfused before the first alloimmunization event is that (1) antigen matching strategy is the same for all patients before the formation of the first antibody and that (2) matching for additional antigens beyond routine Rh and K antigens can potentially affect future exposure to antigens for which antibodies are not formed yet.[48] Overall, our findings suggest that high transfusion load is critical for alloimmunization, but other patient intrinsic factors, such as Hb genotypes, contribute as well.

There are limitations to our study. Firstly, patients who received episodic transfusion were not routinely screened for antibodies after each transfusion, consistent with reports by other groups.[49,50] Although we extended the timeframe for antibody screens, 145 episodically transfused patients did not have a follow-up antibody test after their last transfusion, with a total of 478 units received during the study period. Based on our alloimmunization rate of 0.36 alloantibodies per 100 units transfused, we might have missed 2 alloantibodies among those 478 units for which no follow-up antibody test was performed (478 × 0.36 alloantibodies per 100 RBC units). In addition, a recent study showed that the alloimmunization rate among episodically transfused patients who were screened 2 or 6 months after transfusions was 0.58 alloantibodies per 100 RBC units transfused.[49] When applying the rate to our patients' results, 3 more alloantibodies (478 × 0.58 alloantibodies per 100 RBC units) could have been potentially identified. Because the numbers of missed alloantibodies are small, our findings would not be affected substantially. Secondly, although most patients received transfusions exclusively from our center, some patients received transfusions at other centers, and these exposures were not captured in our analysis. However, in our experience, the number of the outside transfusions was very low. Thirdly, in determining the association of alloimmunization with transfusion during proinflammatory events, our analysis would be strengthened by knowledge of the donor RBC antigen phenotypes. Ideally, only transfused RBC units expressing an antigen corresponding to the formed antibody should be considered as exposure (eg, include only S antigen positive RBC units that were transfused into a patient who formed anti-S). However, RBC units are not routinely phenotyped beyond Rh (D, C, and E) and K antigens. We assumed that RBC units positive for an antigen were equally distributed among the alloantibody-positive and alloantibody-negative transfusions, thus included all the units, regardless of RBC phenotypes.

In summary, our results indicate that transfusion during proinflammatory events increases the risk of alloimmunization, and HU therapy does not reduce alloimmunization. Therefore, judicious use of transfusion, especially during proinflammatory events, should be exercised to prevent alloimmunization in patients with SCD.

Acknowledgments

Authorship

Contribution: Y.Z., J.S.H., and S.T.C. designed the study; P.-L.C., M.B., M.R., and J.Y. collected the clinical data; J.M.G. and G.K. designed and performed statistical analyses; and Y.Z., J.M.G., G.K., J.S.H., and S.T.C. wrote the manuscript.

Conflict-of-interest disclosure: J.S.H. receives consulting fees from CVS Pharmacy, Global Blood Therapeutics, and Forma Therapeutics. The remaining authors declare no competing financial interests.

ORCID profiles: Y.Z., 0000-0001-7254-7564; J.M.G., 0000-0002-0260-0048; J.S.H., 0000-0003-4439-7321; S.T.C., 0000-0003-4333-6965.

Correspondence: Yan Zheng, Department of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Pl, MS342, Memphis, TN 38105; email: yan.zheng@stjude.org.

References

1. Sickle cell disease: data & statistics on sickle cell disease. Centers for Disease Control and Prevention. Accessed 15 June 2022. https://www.cdc.gov/ncbddd/sicklecell/data.html

2. Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. *N Engl J Med*. 1990;322(23):1617-1621.

3. Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. *Blood Adv*. 2020;4(2):327-355.

4. Pirenne F, Yazdanbakhsh K. How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions. *Blood*. 2018;131(25):2773-2781.

5. Coleman S, Westhoff CM, Friedman DF, Chou ST. Alloimmunization in patients with sickle cell disease and underrecognition of accompanying delayed hemolytic transfusion reactions. *Transfusion*. 2019;59(7):2282-2291.

6. Balbuena-Merle R, Hendrickson JE. Red blood cell alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. *Transfus Clin Biol*. 2019;26(2):112-115.

7. Fasano RM, Miller MJ, Chonat S, Stowell SR. Clinical presentation of delayed hemolytic transfusion reactions and hyperhemolysis in sickle cell disease. *Transfus Clin Biol*. 2019;26(2):94-98.

8. Narbey D, Habibi A, Chadebech P, et al. Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease. *Am J Hematol*. 2017;92(12):1340-1348.

9. Nickel RS, Hendrickson JE, Fasano RM, et al. Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series. *Transfusion*. 2016;56(1):107-114.

10. Telen MJ, Afenyi-Annan A, Garrett ME, Combs MR, Orringer EP, Ashley-Koch AE. Alloimmunization in sickle cell disease: changing antibody specificities and association with chronic pain and decreased survival. *Transfusion*. 2015;55(6 Pt 2):1378-1387.

11. Tzounakas VL, Valsami SI, Kriebardis AG, Papassideri IS, Seghatchian J, Antonelou MH. Red cell transfusion in paediatric patients with thalassaemia and sickle cell disease: current status, challenges and perspectives. *Transfus Apher Sci*. 2018;57(3):347-357.

12. da Cunha Gomes EG, Machado LAF, de Oliveira LC, Neto JFN. The erythrocyte alloimmunisation in patients with sickle cell anaemia: a systematic review. *Transfus Med*. 2019;29(3):149-161.

13. Hudson KE, Fasano RM, Karafin MS, Hendrickson JE, Francis RO. Mechanisms of alloimmunization in sickle cell disease. *Curr Opin Hematol*. 2019;26(6):434-441.

14. Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. *Blood*. 2012;120(3):528-537.

15. Casas J, Friedman DF, Jackson T, Vege S, Westhoff CM, Chou ST. Changing practice: red blood cell typing by molecular methods for patients with sickle cell disease. *Transfusion*. 2015;55(6 Pt 2):1388-1393.

16. Chou ST. Transfusion therapy for sickle cell disease: a balancing act. *Hematology Am Soc Hematol Educ Program*. 2013;2013:439-446.

17. Chou ST, Evans P, Vege S, et al. RH genotype matching for transfusion support in sickle cell disease. *Blood*. 2018;132(11):1198-1207.

18. Sippert E, Fujita CR, Machado D, et al. Variant RH alleles and Rh immunisation in patients with sickle cell disease. *Blood Transfus*. 2015;13(1):72-77.

19. Fasano RM, Booth GS, Miles M, et al. Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. *Br J Haematol*. 2015;168(2):291-300.

20. Nickel RS, Osunkwo I, Garrett A, et al. Immune parameter analysis of children with sickle cell disease on hydroxycarbamide or chronic transfusion therapy. *Br J Haematol*. 2015;169(4):574-583.

21. Penkert RR, Hurwitz JL, Thomas P, et al. Inflammatory molecule reduction with hydroxyurea therapy in children with sickle cell anemia. *Haematologica*. 2018;103(2):e50-e54.

22. Hankins JS, Estepp JH, Hodges JR, et al. Sickle Cell Clinical Research and Intervention Program (SCCRIP): a lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood. *Pediatr Blood Cancer*. 2018;65(9):e27228.

23. Chang TC, Haupfear KM, Yu J, et al. A novel algorithm comprehensively characterizes human RH genes using whole-genome sequencing data. *Blood Adv*. 2020;4(18):4347-4357.

24. Hendrickson JE. Red blood cell alloimmunization and sickle cell disease: a narrative review on antibody induction. *Ann Blood*. 2020;5:33.

25. Ramsey G, Smietana SJ. Multiple or uncommon red cell alloantibodies in women: association with autoimmune disease. *Transfusion*. 1995;35(7):582-586.

26. Papay P, Hackner K, Vogelsang H, et al. High risk of transfusion-induced alloimmunization of patients with inflammatory bowel disease. *Am J Med*. 2012;125(7):717.e1-717.e8.

27. Tyler LN, Harville TO, Blackall DP. Multiple alloantibodies after transfusion in an infant treated with infliximab. *N Engl J Med*. 2007;357(20):2092-2093. discussion 2093.

28. Yazer MH, Triulzi DJ, Shaz B, Kraus T, Zimring JC. Does a febrile reaction to platelets predispose recipients to red blood cell alloimmunization? *Transfusion*. 2009;49(6):1070-1075.

29. Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. *Annu Rev Pathol*. 2019;14:263-292.

30. Silva-Junior AL, Garcia NP, Cardoso EC, et al. Immunological hallmarks of inflammatory status in vaso-occlusive crisis of sickle cell anemia patients. *Front Immunol*. 2021;12:559925.

31. Barbu EA, Mendelsohn L, Samsel L, Thein SL. Pro-inflammatory cytokines associate with NETosis during sickle cell vaso-occlusive crises. *Cytokine*. 2020;127:154933.

32. Adegoke SA, Kuti BP, Omole KO, Smith OS, Oyelami OA, Adeodu OO. Acute chest syndrome in sickle cell anaemia: higher serum levels of interleukin-8 and highly sensitive C-reactive proteins are associated with impaired lung function. *Paediatr Int Child Health*. 2018;38(4):244-250.

33. Yazdanbakhsh K. Immunoregulatory networks in sickle cell alloimmunization. *Hematology Am Soc Hematol Educ Program*. 2016;2016(1):457-461.

34. Pal M, Bao W, Wang R, et al. Hemolysis inhibits humoral B-cell responses and modulates alloimmunization risk in patients with sickle cell disease. *Blood*. 2021;137(2):269-280.

35. Nickel RS, Horan JT, Fasano RM, et al. Immunophenotypic parameters and RBC alloimmunization in children with sickle cell disease on chronic transfusion. *Am J Hematol*. 2015;90(12):1135-1141.

36. Zahran AM, Nafady A, Saad K, et al. Effect of hydroxyurea treatment on the inflammatory markers among children with sickle cell disease. *Clin Appl Thromb Hemost*. 2020;26:1076029619895111.

37. Guarda CC, Silveira-Mattos PSM, Yahouédéhou S, et al. Hydroxyurea alters circulating monocyte subsets and dampens its inflammatory potential in sickle cell anemia patients. *Sci Rep*. 2019;9(1):14829.

38. Barbu EA, Dominical VM, Mendelsohn L, Thein SL. Neutrophils remain detrimentally active in hydroxyurea-treated patients with sickle cell disease. *PLoS One*. 2019;14(12):e0226583.

39. Lova L, Groff A, Ravot E, et al. Hydroxyurea exerts a cytostatic but not immunosuppressive effect on T lymphocytes. *AIDS*. 2005;19(2):137-144.

40. Lederman HM, Connolly MA, Kalpatthi R, et al. Immunologic effects of hydroxyurea in sickle cell anemia. *Pediatrics*. 2014;134(4):686-695.

41. Tshilolo L, Tomlinson G, Williams TN, et al. Hydroxyurea for children with sickle cell anemia in Sub-Saharan Africa. *N Engl J Med*. 2019;380(2):121-131.

42. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). *Lancet*. 2011;377(9778):1663-1672.

43. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. *N Engl J Med*. 1995;332(20):1317-1322.

44. Conran N, Fertrin KY, Maximo CdA, Oliveira T, Lobo C, Costa FF. Safe use of hydroxyurea in sickle cell disease patients hospitalized for painful vaso-occlusive episodes: results of the randomized, open-label helps study. *Blood*. 2019;134(Suppl 1):2303-2303.

45. Allali S, Peyrard T, Amiranoff D, et al. Prevalence and risk factors for red blood cell alloimmunization in 175 children with sickle cell disease in a French university hospital reference centre. *Br J Haematol*. 2017;177(4):641-647.

46. Fasano RM, Meyer EK, Branscomb J, White MS, Gibson RW, Eckman JR. Impact of red blood cell antigen matching on alloimmunization and transfusion complications in patients with sickle cell disease: a systematic review. *Transfus Med Rev*. 2019;33(1):12-23.

47. Regalado-Artamendi I, Pérez-Corral AM, García-Morín M, et al. Complete RH and Kell matching related to low alloimmunisation risk in sickle cell disease: prevalence and risk factors of alloimmunisation in a Spanish Tertiary Care National Reference Centre. *Blood Transfus*. 2021;19(4):292-299.

48. Melland C, Nance S. *Technical Mannual: Other Blood Group System and Antigens. 20th ed*. AABB; 2020.

49. Rankin A, Darbari D, Campbell A, et al. Screening for new red blood cell alloantibodies after transfusion in patients with sickle cell disease. *Transfusion*. 2021;61(8):2255-2264.

50. Stack G, Tormey CA. Detection rate of blood group alloimmunization based on real-world testing practices and kinetics of antibody induction and evanescence. *Transfusion*. 2016;56(11):2662-2667.